ACORDA THERAPEUTICS INC

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch ACORQ and buy or sell other stocks, ETFs, and their options commission-free!

About ACORQ

Acorda Therapeutics, Inc. is a biopharmaceutical company that focuses on developing therapies that restore function and improve the lives of people with neurological disorders. Its products include Inbrija (levodopa inhalation powder), Ampyra (dalfampridine), and Fampyra (fampridine). 

CEO
Ronald Cohen, MD
CEORonald Cohen, MD
Employees
Employees
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1995
Founded1995
Employees
Employees

ACORQ Key Statistics

Market cap
16.80K
Market cap16.80K
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
21.30K
Average volume21.30K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$18.00
52 Week high$18.00
52 Week low
$0.0131
52 Week low$0.0131

Stock Snapshot

ACORDA THERAPEUTICS INC(ACORQ) stock is priced at $0.01, giving the company a market capitalization of 16.8K.

During the trading day, ACORDA THERAPEUTICS INC(ACORQ) stock saw an opening price of —, a peak of —, and a bottom of —.

Trading volume for ACORDA THERAPEUTICS INC(ACORQ) stock has reached 0, versus its average volume of 21.3K.

The stock's 52-week range extends from a low of $0.01 to a high of $18.00.

The stock's 52-week range extends from a low of $0.01 to a high of $18.00.

People also own

Based on the portfolios of people who own ACORQ. This list is generated using Robinhood data, and it’s not a recommendation.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.